Cardiotonic Agents

"Cardiotonic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).

Descriptor ID	D002316
MeSH Number(s)	D27.505.954.411.222 D27.720.799.080
Concept/Terms	Cardiotonic Agents Cardiotonic Agents Cardiac Stimulants Inotropic Agents, Positive Cardiac Cardiotonic Drugs Cardiotonics Myocardial Stimulants Cardioprotective Agents

Below are MeSH descriptors whose meaning is more general than "Cardiotonic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Cardiovascular Agents [D27.505.954.411]
Cardiotonic Agents [D27.505.954.411.222]
Specialty Uses of Chemicals [D27.720]
Protective Agents [D27.720.799]
Cardiotonic Agents [D27.720.799.080]

Below are MeSH descriptors whose meaning is more specific than "Cardiotonic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cardiotonic Agents" by people in this website by year, and whether "Cardiotonic Agents" was a major or minor topic of these publications.

Bar chart showing 60 publications over 26 distinct years, with a maximum of 6 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	1	0	1
1994	0	2	2
1995	2	0	2
1996	1	1	2
1997	0	1	1
1998	1	0	1
1999	0	1	1
2000	1	2	3
2001	1	1	2
2002	2	2	4
2003	1	2	3
2004	4	2	6
2005	2	1	3
2006	1	2	3
2007	2	1	3
2009	2	1	3
2010	0	1	1
2012	1	0	1
2013	3	0	3
2014	1	1	2
2015	0	1	1
2016	0	2	2
2017	2	0	2
2018	1	3	4
2019	1	0	1
2020	2	1	3

Below are the most recent publications written about "Cardiotonic Agents" by people in Profiles.

Hawn JM, Bauer SR, Yerke J, Li M, Wang X, Reddy AJ, Mireles-Cabodevila E, Sacha GL. Effect of Phenylephrine Push Before Continuous Infusion Norepinephrine in Patients With Septic Shock. Chest. 2021 05; 159(5):1875-1883.

View in: PubMed
Silverman DN, Houston BA, Tedford RJ. Old Drug, New Trick? Oral Milrinone for Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2020 07 07; 9(13):e017170.

View in: PubMed
Lam PH, Packer M, Gill GS, Wu WC, Levy WC, Zile MR, Brar V, Arundel C, Cheng Y, Singh SN, Allman RM, Fonarow GC, Ahmed A. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Am J Med. 2020 10; 133(10):1187-1194.

View in: PubMed
Hornik CP, Yogev R, Mourani PM, Watt KM, Sullivan JE, Atz AM, Speicher D, Al-Uzri A, Adu-Darko M, Payne EH, Gelber CE, Lin S, Harper B, Melloni C, Cohen-Wolkowiez M, Gonzalez D. Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. J Clin Pharmacol. 2019 12; 59(12):1606-1619.

View in: PubMed
Dewan P, Jhund PS, Shen L, Petrie MC, Abraham WT, Atif Ali M, Chen CH, Desai AS, Dickstein K, Huang J, Kiatchoosakun S, Kim KS, Køber L, Lai WT, Liao Y, Mogensen UM, Oh BH, Packer M, Rouleau JL, Shi V, Sibulo AS, Solomon SD, Sritara P, Swedberg K, Tsutsui H, Zile MR, McMurray JJV. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.

View in: PubMed
Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE, McLeod CJ, Oken KR, Patton KK, Pellegrini CN, Selzman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Circulation. 2019 08 20; 140(8):e333-e381.

View in: PubMed
Zhou S, Wang J, Yin X, Xin Y, Zhang Z, Cui T, Cai J, Zheng Y, Liu Q, Cai L. Nrf2 expression and function, but not MT expression, is indispensable for sulforaphane-mediated protection against intermittent hypoxia-induced cardiomyopathy in mice. Redox Biol. 2018 10; 19:11-21.

View in: PubMed
Vaduganathan M, Claggett B, Packer M, McMurray JJV, Rouleau JL, Zile MR, Swedberg K, Solomon SD. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. JACC Heart Fail. 2018 07; 6(7):564-569.

View in: PubMed
Meystre SM, Kim Y, Gobbel GT, Matheny ME, Redd A, Bray BE, Garvin JH. Congestive heart failure information extraction framework for automated treatment performance measures assessment. J Am Med Inform Assoc. 2017 Apr 01; 24(e1):e40-e46.

View in: PubMed
Gurel E, Karvar S, Yucesan B, Eker I, Sameeullah M. An Overview of Cardenolides in Digitalis - More Than a Cardiotonic Compound. Curr Pharm Des. 2017; 23(34):5104-5114.

View in: PubMed

People

Explore

Similar Concepts

Top Journals